The Partnering Agreements with Onyx Pharmaceuticals report provides an in-depth insight into the partnering interests and activites of one of the worlds leading biopharma companies.
Onyx Pharmaceuticals is expected to receive initial takeover bids as soon as this week after attracting interest from a few drugmakers.
Sorry, your search returned no results.
Onyx Pharmaceuticals has bowed out of its $550 million collaboration deal covering two JAK2 inhibitor programs in development at Singapore’s S BIO.
Cancer drug developer Calithera Biosciences Inc. is seeking $80 million through an initial public offering financing, the company said in a U.S. Securities and Exchange Commission filing Monday